613
Views
5
CrossRef citations to date
0
Altmetric
Review

The effect of stimulants on irritability in autism comorbid with ADHD: a systematic review

, &
Pages 1547-1555 | Published online: 06 Jun 2019

References

  • Leibenluft E. Severe mood dysregulation, irritability, and the diagnostic boundaries of bipolar disorder in youths. Am J Psychiatry. 2011;168:129–142. doi:10.1176/appi.ajp.2010.1005076621123313
  • Eyre O, Langley K, Stringaris A, Leibenluft E, Collishaw S, Thapar A. Irritability in ADHD: associations with depression liability. J Affect Disord. 2017;215:281–287. doi:10.1016/j.jad.2017.03.05028363151
  • Harty SC, Gnagy EM, Pelham WE Jr., Molina BSG. Anger-irritability as a mediator of attention deficit hyperactivity disorder risk for adolescent alcohol use and the contribution of coping skills. J Child Psychol Psychiatry. 2017;58:555–563. doi:10.1111/jcpp.1266827991655
  • Pan PY, Fu AT, Yeh CB. Aripiprazole/methylphenidate combination in children and adolescents with disruptive mood dysregulation disorder and attention-deficit/hyperactivity disorder: an open-label study. J Child Adolesc Psychopharmacol. 2018;28:682–689. doi:10.1089/cap.2018.006830148656
  • Winters DE, Fukui S, Leibenluft E, Hulvershorn LA. Improvements in Irritability with open-label methylphenidate treatment in youth with comorbid attention deficit/hyperactivity disorder and disruptive mood dysregulation disorder. J Child Adolesc Psychopharmacol. 2018;28:298–305. doi:10.1089/cap.2017.012429708762
  • Shaw P, Stringaris A, Nigg J, Leibenluft E. Emotion dysregulation in attention deficit hyperactivity disorder. Am J Psychiatry. 2014;171:276–293. doi:10.1176/appi.ajp.2013.1307096624480998
  • Stuckelman ZD, Mulqueen JM, Ferracioli-Oda E, et al. Risk of irritability with psychostimulant treatment in children with ADHD: a meta-analysis. J Clin Psychiatry. 2017;78:e648–e655. doi:10.4088/JCP.15r1060128682529
  • Coghill DR, Banaschewski T, Nagy P, et al. Long-term safety and efficacy of lisdexamfetamine dimesylate in children and adolescents with ADHD: a phase IV, 2-Year, open-label study in Europe. CNS Drugs. 2017;31:625–638. doi:10.1007/s40263-017-0443-y28667569
  • Wigal SB, Childress A, Berry SA, et al. Efficacy and safety of a chewable methylphenidate extended-release tablet in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2017;27:690–699. doi:10.1089/cap.2016.017728557548
  • Wigal SB, Kollins SH, Childress AC, Squires L, Study G. A 13 hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2009;3:17. doi:10.1186/1753-2000-3-1719508731
  • Childress AC, Kollins SH, Cutler AJ, Marraffino A, Sikes CR. Efficacy, safety, and tolerability of an extended-release orally disintegrating methylphenidate tablet in children 6–12 years of age with attention-deficit/hyperactivity disorder in the laboratory classroom setting. J Child Adolesc Psychopharmacol. 2017;27:66–74. doi:10.1089/cap.2016.000227183299
  • Fernandez de la Cruz L, Simonoff E, McGough JJ, Halperin JM, Arnold LE, Stringaris A. Treatment of children with attention-deficit/hyperactivity disorder (ADHD) and irritability: results from the multimodal treatment study of children with ADHD (MTA). J Am Acad Child Adolesc Psychiatry. 2015;54:62–70.e63. doi:10.1016/j.jaac.2014.10.00625524791
  • Goldstein S, Schwebach AJ. The comorbidity of pervasive developmental disorder and attention deficit hyperactivity disorder: results of a retrospective chart review. J Autism Dev Disord. 2004;34:329–339.15264500
  • Ghanizadeh A. Co-morbidity and factor analysis on attention deficit hyperactivity disorder and autism spectrum disorder DSM-IV-derived items. J Res med sci. 2012;17:368–372.23267399
  • Lee DO, Ousley OY. Attention-deficit hyperactivity disorder symptoms in a clinic sample of children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16:737–746. doi:10.1089/cap.2006.16.73717201617
  • Campbell M, Small AM, Collins PJ, Friedman E, David R, Genieser N. Levodopa and levoamphetamine: a crossover study in young schizophrenic children. Curr Ther Res Clin Exp. 1976;19:70–86.812668
  • Aman MG, Pejeau C, Osborne P, Rojahn J, Handen B. Four-year follow-up of children with low intelligence and ADHD. Res Dev Disabil. 1996;17:417–432.8946568
  • Aman MG. Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder. Semin Pediatr Neurol. 2004;11:225–228.15575418
  • Stigler KA, Desmond LA, Posey DJ, Wiegand RE, McDougle CJ. A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2004;14:49–56. doi:10.1089/10445460477384048115142391
  • Nickels KC, Katusic SK, Colligan RC, Weaver AL, Voigt RG, Barbaresi WJ. Stimulant medication treatment of target behaviors in children with autism: a population-based study. J Dev Behav Pediatr. 2008;29:75–81.18478626
  • Posey DJ, Michael GA, Arnold LE et al. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiat. 2005;62:1266–1274. doi:10.1001/archpsyc.62.11.1266
  • Santosh PJ, Baird G, Pityaratstian N, Tavare E, Gringras P. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. Child Care Health Dev. 2006;32:575–583. doi:10.1111/j.1365-2214.2006.00631.x16919137
  • Ghanizadeh A, Tordjman S, Jaafari N. Aripiprazole for treating irritability in children & adolescents with autism: A systematic review. Indian J Med Res. 2015;142:269–275. doi:10.4103/0971-5916.16658426458342
  • Ghanizadeh A, Sahraeizadeh A, Berk M. A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry Hum Dev. 2014;45:185–192. doi:10.1007/s10578-013-0390-x23801256
  • Ghanizadeh A, Moghimi-Sarani E. A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders. BMC Psychiatry. 2013;13:196. doi:10.1186/1471-244x-13-19623886027
  • Ghanizadeh A, Ayoobzadehshirazi A. A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism. Pediatr Neurol. 2015;52:77–81. doi:10.1016/j.pediatrneurol.2014.09.01725451017
  • Abanilla PK, Hannahs GA, Wechsler R, Silva RR. The use of psychostimulants in pervasive developmental disorders. Psychiat Quart. 2005;76:271–281. doi:10.1007/s11126-005-2980-716080422
  • Accordino RE, Kidd C, Politte LC, Henry CA, McDougle CJ. Psychopharmacological interventions in autism spectrum disorder. Expert Opin Pharmacother. 2016;17:937–952. doi:10.1517/14656566.2016.115453626891879
  • Aman MG, Farmer CA, Hollway J, Arnold LE. Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders. Child Adolesc Psychiatr Clin N Am. 2008;17:713–738. doi:10.1016/j.chc.2008.06.00918775366
  • Cauffeld JS. Medication use in autism spectrum disorders: what is the evidence? Formulary. 2013;48:161–168.
  • Posey DJ, McDougle CJ. The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harv Rev Psychiatry. 2000;8:45–63.10902094
  • Davis NO, Kollins SH. Treatment for co-occurring attention deficit/hyperactivity disorder and autism spectrum disorder. Neurotherapeutics. 2012;9:518–530. doi:10.1007/s13311-012-0126-922678458
  • Doyle CA, McDougle CJ. Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan. Dialogues Clin Neurosci. 2012;14:263–279.23226952
  • Santosh PJ, Singh J. Drug treatment of autism spectrum disorder and its comorbidities in children and adolescents. BJ Psych Adv. 2016;22:151–161. doi:10.1192/apt.bp.115.014597
  • Beherec L, Quilici G, Rosier A, Gerardin P, Campion D, Guillin O. [Pharmacological treatments in patients with pervasive developmental disorders: A review]. L’Encephale. 2014;40:188–196. doi:10.1016/j.encep.2012.01.014
  • Fung LK, Mahajan R, Nozzolillo A, et al. Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis. Pediatrics. 2016;137:S124–S135. doi:10.1542/peds.2015-2851K26908468
  • Benvenuto A, Battan B, Porfirio MC, Curatolo P. Pharmacotherapy of autism spectrum disorders. Brain Dev. 2013;35:119–127. doi:10.1016/j.braindev.2012.03.01522541665
  • Handen BL, Taylor J, Tumuluru R. Psychopharmacological treatment of ADHD symptoms in children with autism spectrum disorder. Int J Adolesc Med Health. 2011;23:167–173. doi:10.1515/IJAMH.2011.03922191179
  • Blankenship K, Janicak PG. Pharmacotherapy of autism spectrum disorders. Psychopharm Rev. 2011;46:81–88. doi:10.1097/01.PSYPHR.0000407109.91433.4C
  • Kolevzon A. The pharmacologic treatment of attention deficit and hyperactivity in autism. Prim Psychiatry. 2009;16:55–60.
  • Canitano R, Scandurra V. Psychopharmacology in autism: an update. Prog Neuro-Psychopharmacol Biol Psychiatry. 2011;35:18–28. doi:10.1016/j.pnpbp.2010.10.015
  • McCracken JT, Badashova KK, Posey DJ, et al. Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders. Pharmacogenomics J. 2014;14:295–302. doi:10.1038/tpj.2013.2323856854
  • Posey DJ, Aman MG, McCracken JT, et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiat. 2007;61:538–544. doi:10.1016/j.biopsych.2006.09.02817276750
  • Jahromi LB, Kasari CL, McCracken JT, et al. Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. J Autism Dev Disord. 2009;39:395–404. doi:10.1007/s10803-008-0636-918752063
  • Birmaher B, Quintana H, Greenhill LL. CASE STUDY methylphenidate treatment of hyperactive autistic children. J Am Acad Child Adolesc Psychiatry. 1988;27:248–251. doi:10.1097/00004583-198803000-000203360732
  • Di Martino A, Melis G, Cianchetti C, et al. Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study. J Child Adolesc Psychopharmacol. 2004;14:207–218. doi:10.1089/104454604164901115319018
  • Kim SJ, Shonka S, French WP, Strickland J, Miller L, Stein MA. Dose-Response Effects Of Long-Acting Liquid Methylphenidate In Children With Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): a pilot study. J Autism Dev Disord. 2017;47:2307–2313. doi:10.1007/s10803-017-3125-128474229
  • Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord. 2000;30:245–255.11055460
  • Quintana H, Birmaher B, Stedge D, et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord. 1995;25:283–294. doi:10.1007/BF021792897559293